plerixafor has been researched along with Acute Myelogenous Leukemia in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 26 (72.22) | 24.3611 |
| 2020's | 6 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, W; Feng, X; Liu, X; Ren, Q; Wang, H; Wang, L; Wang, R; Yang, F; Yang, X; Zhang, D; Zhang, Y; Zheng, G | 1 |
| Chevassut, T; Ladikou, EE; Pepper, AG; Pepper, CJ | 1 |
| Andreeff, M; Borthakur, G; Chen, HC; Cortes, JE; Daver, N; Huang, X; Kadia, T; Kantarjian, H; Kelly, MA; Konopleva, M; McQueen, T; Patel, KP; Ravandi, F; Wang, RY; Zeng, Z | 1 |
| Allan, DS; Fulcher, J; Maganti, H; Sabloff, M; Shorr, R; Visram, A | 1 |
| Hu, Z; Su, L; Yang, YG | 1 |
| Binner, M; Bornhäuser, M; Bray, LJ; Körner, Y; von Bonin, M; Werner, C | 1 |
| Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T | 1 |
| Allan, JN; Askin, G; Christos, P; Guzman, ML; Hassane, DC; Ritchie, E; Roboz, GJ; Scandura, J | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Elhamri, M; Hayette, S; Heiblig, M; Plesa, A; Raffoux, E; Thomas, X | 1 |
| Han, AR; Hwang, HS; Kim, HJ; Lee, JY; Min, WS; Park, GS | 1 |
| Amarteifio, S; Ang, H; Duarte, D; Hawkins, ED; Kong, IY; Lo Celso, C; Pruessner, G; Ruivo, N | 1 |
| Chow, S; Gupta, V; Hedley, DW; Kim, DD; Kuruvilla, J; Lipton, JH; Loach, D; Malhotra, S; Messner, HA; Michelis, FV; Viswabandya, A | 1 |
| Amador, C; Becker, M; Hang, Y; Hyde, RK; Oupický, D; Richter, L; Wang, Y; Williams, J; Xie, Y | 1 |
| Baggerly, KA; Benton, CB; Champlin, R; Chen, J; Konoplev, S; Konopleva, M; Liu, W; Lu, H; Shpall, E; Wang, RY; Zeng, Z | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Lum, LG; Masood, A; Ratanatharathorn, V; Uberti, JP | 1 |
| Culligan, DJ; Dong, B; Hay, AE; Lawrie, A; Robinson, N | 1 |
| Brown, P; Magoon, D; McIntyre, E; Sison, EA | 1 |
| Willyard, C | 1 |
| Andreeff, M; Hatanaka, Y; Hsu, FJ; Jin, L; Konopleva, M; Miida, T; Shi, YX; Shikami, M; Tabe, Y; Zeng, Z | 1 |
| Assanelli, A; Bellio, L; Ciceri, F; Coppola, M; Corti, C; De Freitas, T; Gattillo, S; Malabarba, L; Malato, S; Marktel, S; Milani, R; Rizzo, L | 1 |
| Alousi, A; Anderlini, P; Andreeff, M; Benton, CB; Champlin, R; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Kebriaei, P; Konopleva, M; Lu, H; McMullin, B; Nieto, Y; Parmar, S; Popat, U; Qiao, W; Rondon, G; Schober, W; Shpall, E; Thall, PF; Wang, RY; Woodworth, G; Zeng, Z | 1 |
| Han, AR; Kim, HJ; Kim, SH; Lee, JY; Min, WS; Park, G | 1 |
| Bernasconi, P; Boni, M; Calvello, C; Dambruoso, I; Farina, M | 1 |
| Kong, PY; Ma, YY; Shen, ZH; Zeng, DF; Zhang, X | 1 |
| Hou, J; Leung, AY; Liang, R; Luo, T; Ng, KL; Sun, D | 1 |
| Abboud, CN; Andreeff, M; DiPersio, JF; Eades, W; Fletcher, TR; Jacoby, MA; Konopleva, MY; McFarland, K; Reineck, T; Rettig, MP; Shannon, W; Stockerl-Goldstein, K; Stone, RM; Uy, GL; Westervelt, P | 1 |
| Bornhäuser, M; Brenner, S; Ehninger, G; Fierro, FA; Illmer, T; Jacobi, A; Knoth, H; Oelschlaegel, U | 1 |
| Amariglio, N; Baron, S; Benzion, K; Deutsch, V; Eisenbach, M; Golan, T; Jacob-Hirsch, J; Kay, S; Naparstek, E; Petit, I; Rechavi, G; Tavor, S | 1 |
| Amorim, M; Colmone, A; Jablonski, E; Pontier, AL; Sipkins, DA; Wang, S | 1 |
| Leotta, S; Marturano, E; Mauro, E; Milone, G; Poidomani, M; Spadaro, A | 1 |
| Atadja, P; Balusu, R; Bhalla, K; Buckley, KM; Chong, DG; Fiskus, W; Fujii, N; Mandawat, A; Navenot, JM; Peiper, SC; Rao, R; Robbins, K; Ustun, C; Wang, ZX | 1 |
| Abraham, M; Begin, M; Beider, K; Eizenberg, O; Engelhard, D; Galun, E; Hardan, I; Nagler, A; Peled, A; Pikarsky, E; Wald, H; Wald, O; Weiss, ID; Zeira, E | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Abdelouahab, H; Bawa, O; Betems, A; Coppo, P; De Botton, S; Fujii, N; Gonin, P; Ito, M; Joulin, V; Louache, F; Opolon, P; Pasquier, F; Patel, S; Shen, S; Solary, E; Vainchenker, W; Willekens, C; Wittner, M; Zhang, Y | 1 |
| Abboud, CN; Bechelli, J; Bridger, G; Liesveld, JL; Lu, C; Phillips, G; Rosell, K | 1 |
4 review(s) available for plerixafor and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzylamines; Bone Marrow; Cell Adhesion; Cell Hypoxia; Cell Movement; Cell-Derived Microparticles; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplastic Stem Cells; Peptides; Peptides, Cyclic; Pyridines; Receptors, CXCR4; Signal Transduction; Stem Cell Niche; Stromal Cells; Tumor Microenvironment | 2020 |
Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies.
Topics: Animals; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Prognosis | 2020 |
Role of CXCR4 in the progression and therapy of acute leukaemia.
Topics: Benzylamines; Chemokine CXCL12; Cyclams; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Receptors, CXCR4; Signal Transduction; Small Molecule Libraries | 2021 |
Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzylamines; Bone Marrow; Cell Hypoxia; Cell Lineage; Chemokine CXCL12; Clinical Trials as Topic; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclams; Diphosphonates; Disease Models, Animal; Heterocyclic Compounds; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplastic Stem Cells; Protein Kinase Inhibitors; Receptors, CXCR4; Stem Cell Niche; Stromal Cells; Transplantation, Heterologous; Tumor Microenvironment | 2016 |
10 trial(s) available for plerixafor and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Sorafenib; Survival Rate | 2020 |
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult | 2017 |
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Cyclams; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds; Humans; Interleukin-2 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Benzylamines; Cyclams; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 2018 |
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.
Topics: Adult; Allografts; Benzylamines; Busulfan; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Proteomics; Signal Transduction; Transplantation Conditioning; Vidarabine | 2019 |
Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.
Topics: Adult; Aged; Benzylamines; Compassionate Use Trials; Cyclams; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Topics: Adult; Aged; Allografts; Antigens, CD34; Benzylamines; Blood Cell Count; Carcinoma, Renal Cell; Colony-Forming Units Assay; Cyclams; Drug Synergism; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Kidney Neoplasms; Lenograstim; Leukapheresis; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Pain; Parents; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Siblings; Treatment Outcome | 2015 |
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Stem Cell Transplantation | 2017 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Receptors, CXCR4; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2012 |
22 other study(ies) available for plerixafor and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.
Topics: Adolescent; Adoptive Transfer; Animals; Antineoplastic Agents, Immunological; Benzylamines; Bone Marrow; Cell Movement; Chemokine CCL3; Chemokine CXCL12; Child; Child, Preschool; Cyclams; Disease Models, Animal; Disease Progression; Female; Forkhead Transcription Factors; Gene Expression Regulation, Leukemic; Gene Knock-In Techniques; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Maraviroc; Mice; Mice, Transgenic; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Receptors, CCR; Signal Transduction; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2020 |
A three-dimensional
Topics: Benzylamines; Biomarkers; Cell Communication; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cyclams; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Receptors, CXCR4; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzylamines; Cell Line, Tumor; Cyclams; Cytarabine; Disease Models, Animal; Heterocyclic Compounds; Humans; Immunomodulation; Immunotherapy; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Receptors, CXCR4; Tumor Microenvironment | 2019 |
Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
Topics: Animals; Antineoplastic Agents; Benzylamines; Bone Marrow; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Drug Resistance, Neoplasm; Heterocyclic Compounds; Intravital Microscopy; Leukemia, Myeloid, Acute; Mice; Microscopy, Confocal; Microscopy, Fluorescence, Multiphoton; Receptors, CXCR4; Tumor Microenvironment | 2019 |
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
Topics: Adult; Anti-HIV Agents; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation, Homologous | 2019 |
Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Cholesterol; Core Binding Factor Alpha 2 Subunit; Cyclams; Disease Models, Animal; Drug Carriers; Female; Gene Knock-In Techniques; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Transgenic; Nanoparticles; Oncogene Proteins, Fusion; Polyelectrolytes; Receptors, CXCR4; RNA, Small Interfering | 2020 |
A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2013 |
Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Chemotaxis; Child; Cyclams; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Stromal Cells; Up-Regulation | 2013 |
Stem cells: bad seeds.
Topics: Animals; Benzylamines; Biomarkers, Tumor; Cell Division; Chemokine CXCL12; Cyclams; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Leukemia, Myeloid, Acute; Mice; Models, Biological; Neoplastic Stem Cells; Proto-Oncogene Proteins c-hck | 2013 |
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Coculture Techniques; Cyclams; Cytarabine; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Neoplasm Transplantation; Receptors, CXCR4; Transforming Growth Factor beta; Tumor Microenvironment | 2013 |
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.
Topics: Adult; Aged; Benzylamines; Busulfan; Cell Movement; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzylamines; Bone Marrow Cells; Cell Movement; Chemokine CXCL12; Cyclams; Cytarabine; Female; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Neoplasms, Experimental; Neoplastic Stem Cells; Receptors, CXCR4; Tumor Microenvironment | 2015 |
AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Biomimetic Materials; Cell Adhesion; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cyclams; Cytarabine; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia; Leukemia, Myeloid, Acute; Polystyrenes; Receptor Cross-Talk; Receptors, CXCR4; Stromal Cells | 2016 |
Characterization of Drug Effect on Leukemia Cells Through Single Cell Assay With Optical Tweezers and Dielectrophoresis.
Topics: Antineoplastic Agents; Benzylamines; Cell Adhesion; Cell Line, Tumor; Cell Survival; Chemokine CXCL12; Coculture Techniques; Cyclams; Electrophoresis; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Optical Tweezers; Receptors, CXCR4; Signal Transduction; Single-Cell Analysis; Stromal Cells | 2016 |
Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzylamines; Cell Movement; Chemokine CXCL12; Cyclams; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, CXCR4; Recurrence | 2009 |
The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
Topics: Antibodies, Monoclonal; Benzylamines; Cell Differentiation; Cell Division; Cell Survival; Chemokine CXCL12; Cyclams; Gene Expression Regulation, Leukemic; Granulocytes; Heterocyclic Compounds; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oligonucleotide Array Sequence Analysis; Pancreatic Elastase; Receptors, CXCR4; U937 Cells | 2008 |
Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells.
Topics: Animals; Antigens, CD34; Benzylamines; Bone Marrow; Cell Count; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Factor; Stem Cell Niche; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest.
Topics: Adult; Benzylamines; Blood Donors; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Transplantation, Homologous | 2011 |
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Cyclams; Drug Synergism; Heterocyclic Compounds; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Peptides, Cyclic; Receptors, CXCR4; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2010 |
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Apoptosis; Benzylamines; Chemokine CXCL12; Cyclams; Heterocyclic Compounds; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Peptides; Receptors, CXCR4 | 2011 |
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-HIV Agents; Apoptosis; Benzylamines; Chemokine CXCL12; Child, Preschool; Cyclams; Disease Models, Animal; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Receptors, CXCR4; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.
Topics: Animals; Antigens, CD34; Benzylamines; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Coculture Techniques; Culture Media; Cyclams; Heterocyclic Compounds; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation | 2007 |